1-7 of 7
Maureen C. Ryan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies

Maureen C. Ryan, Maria Corinna Palanca-Wessels, Brian Schimpf, Kristine A. Gordon, Heather Kostner, Brad Meyer, Changpu Yu, Heather A. Van Epps, Dennis Benjamin
Journal: Blood
Blood (2017) 130 (18): 2018–2026.
https://doi.org/10.1182/blood-2017-04-779389
Published: 2017
Includes: Supplemental data
Journal Articles

Denintuzumab Mafodotin Stimulates Immune Responses and Synergizes with CD20 Antibodies to Heighten Anti-Tumor Activity in Preclinical Models of Non-Hodgkin Lymphoma

Heather A. Van Epps, PhD, Ryan Heiser, PhD, Anthony Cao, PhD, Kerry Klussman, Changpu Yu, Ivan Stone, Jason Neale, PhD, Shyra J. Gardai, PhD, Che-Leung Law, PhD, Maureen C. Ryan, PhD
Journal: Blood
Blood (2016) 128 (22): 4177.
https://doi.org/10.1182/blood.V128.22.4177.4177
Published: 2016
Journal Articles

SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, Christine O'Day, PhD, Steve Alley, PhD, Martha Anderson, Kim Emmerton, Weipeng Zeng, Megan M. O'Meara, MD, Eric J. Feldman, MD, Dana A. Kennedy, Maureen C. Ryan, PhD, Dennis Benjamin, PhD
Journal: Blood
Blood (2015) 126 (23): 3785.
https://doi.org/10.1182/blood.V126.23.3785.3785
Published: 2015
Journal Articles

SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies

Maureen C. Ryan, PhD, Brian Schimpf, Martha Anderson, Weiping Zeng, Kim Emmerton, Jamie Miyamoto, Heather Kostner, Changpu Yu, Heather Van Epps, PhD, Laurie Tatalick, DVM, PhD DACVP, Dennis Benjamin, PhD
Journal: Blood
Blood (2015) 126 (23): 594.
https://doi.org/10.1182/blood.V126.23.594.594
Published: 2015
Journal Articles

SGN-CD33A in Combination with Cytarabine or Hypomethylating Agents Demonstrates Enhanced Anti-Leukemic Activity in Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, MD, Martha Anderson, Kim Emmerton, Weiping Zeng, MD, Megan M. O'Meara, MD, Dana A. Kennedy, PharmD, BCOP, Maureen C. Ryan, PhD, Dennis R. Benjamin, PhD
Journal: Blood
Blood (2014) 124 (21): 3739.
https://doi.org/10.1182/blood.V124.21.3739.3739
Published: 2014
Journal Articles

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

May S. Kung Sutherland, Roland B. Walter, Scott C. Jeffrey, Patrick J. Burke, Changpu Yu, Heather Kostner, Ivan Stone, Maureen C. Ryan, Django Sussman, Robert P. Lyon, Weiping Zeng, Kimberly H. Harrington, Kerry Klussman, Lori Westendorf, David Meyer, Irwin D. Bernstein, Peter D. Senter, Dennis R. Benjamin, Jonathan G. Drachman, Julie A. McEarchern
Journal: Blood
Blood (2013) 122 (8): 1455–1463.
https://doi.org/10.1182/blood-2013-03-491506
Published: 2013
Includes: Supplemental data
Journal Articles

SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

May S.K. Sutherland, PhD, Roland B. Walter, MD, PhD, Scott C. Jeffrey, PhD, Patrick J. Burke, PhD, Changpu Yu, MD, Kimberly H. Harrington, BS, Ivan Stone, BS, Maureen C. Ryan, PhD, Django Sussman, PhD, Weiping Zeng, MD, Dennis R. Benjamin, PhD, Irwin D. Bernstein, MD, Peter D. Senter, PhD, Jonathan G. Drachman, MD, Julie A. McEarchern, PhD
Journal: Blood
Blood (2012) 120 (21): 3589.
https://doi.org/10.1182/blood.V120.21.3589.3589
Published: 2012